Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2017
Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report that familiarity is a key driver of drug selection within a class, but clinical factors are significant both for physicians and MCOs. Cost-control measures are critical for MCOs, and have a moderate impact on prescribing decisions.
Pharmacoeconomic data are anticipated to be of increasing importance, especially with the launch of additional therapies within the LABA/LAMA class and the new LABA/LAMA/ICS FDC class.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
